Literature DB >> 15919321

Midterm clinical experience with microwave surgical ablation of atrial fibrillation.

Thomas A Molloy1.   

Abstract

PURPOSE: Multiple energy sources and lesion sets have been described as an alternative to the conventional cut-and-sew Maze procedure for atrial fibrillation (AF). Described are midterm results with microwave (MW) energy and a single left-sided lesion set so that surgeons can evaluate whether this approach may be appropriate for their patients. DESCRIPTION: Twenty-nine consecutive patients with chronic (86%) or paroxysmal (14%) AF, undergoing surgery for coexisting heart disease, also underwent MW AF ablation by the use of a single lesion set. A single preoperative and postoperative management regimen was used. EVALUATION: One hundred percent electrocardiogram follow-up was obtained. At minimum follow-up of 4 months (mean 315 days), 23 of 28 patients (86%) were in stable sinus rhythm.
CONCLUSIONS: The simplified lesion set performed with MW energy compares favorably with the cut-and-sew Maze procedure for patients presenting with AF and coexisting acquired cardiac disease. Connecting lesions to the mitral annulus and right-sided lesions may add potential morbidity without additional efficacy.

Entities:  

Mesh:

Year:  2005        PMID: 15919321     DOI: 10.1016/j.athoracsur.2004.06.104

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  3 in total

Review 1.  Microwave tissue ablation: biophysics, technology, and applications.

Authors:  Christopher L Brace
Journal:  Crit Rev Biomed Eng       Date:  2010

2.  Epicardial Ablation on the Beating Heart: Limited Efficacy of a Novel, Cooled Radiofrequency Ablation Device.

Authors:  Anson M Lee; Abdulhameed Aziz; Shun-Ichiro Sakamoto; Richard B Schuessler; Ralph J Damiano
Journal:  Innovations (Phila)       Date:  2009

3.  Strategies in the surgical management of atrial fibrillation.

Authors:  Leanne Harling; Thanos Athanasiou; Hutan Ashrafian; Justin Nowell; Antonios Kourliouros
Journal:  Cardiol Res Pract       Date:  2011-06-12       Impact factor: 1.866

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.